Background {#Sec1}
==========

In recent years, an increased incidence of invasive aspergillosis (IA) has affected the lives of many immunocompromised patients \[[@CR1]\]. It has been reported that some *Aspergillus* strains are resistant to azoles, polyenes and echinocandins, thus reducing the effectiveness of treatments \[[@CR2]\]. Combinations of azoles and echinocandins against *Aspergillus* or azole-resistant *Aspergillus* are known to be effective for the treatment of serious infections \[[@CR2], [@CR3]\]. Moreover, new imidazoles, such as lanoconazole and luliconazole, strongly inhibit the growth of *Aspergillus spp.* \[[@CR4], [@CR5]\]. An additional challenge is the presence of *Aspergillus* biofilms, which are thought to contribute to virulence in IA and aspergilloma \[[@CR6]\]. In vivo findings show that in sinus aspergillomas, *A. fumigatus* may grow as a typical biofilm characterized by hyphae anchored within an extracellular matrix. Similar biofilms have also been observed on contact lenses in fungal keratitis, in bronchoalveolar lavage fluids of chronic pulmonary aspergillosis and in neutropenic cancer patients with IA \[[@CR6], [@CR7]\]. Without adequate therapy, these diseases result in long-term suffering of patients. The minimal inhibitory concentrations (MICs) of antifungals against the biofilm form of *Aspergillus* spp. are predominantly high, particularly among the azoles \[[@CR6], [@CR8]\]. Therefore, there is an urgent necessity for new treatment approaches.

Histone deacetylases (HDACs) are enzymes that specifically remove acetyl groups from lysine residues on histones. HDACs also act on other cellular proteins. This deacetylation can affect gene regulation as well as other cellular functions \[[@CR9]\]. HDAC inhibitors are able to block the cell cycle, induce apoptosis, and terminate cellular differentiation \[[@CR9]\]. It has been reported that combinations of HDAC inhibitors with an azole can reverse fungal resistance to azoles by blocking the HSP90-dependent response \[[@CR10]\]. Givinostat, MGCD290 and trichostatin A (TSA) have been reported to act synergistically with azoles against *Candida* and *Aspergillus* in vitro \[[@CR10]--[@CR13]\]. Hence, the combination of HDAC inhibitors and antifungals is a promising approach to address fungal drug resistance. Vorinostat (suberoylanilide hydroxamic acid or SAHA) is a novel HDAC inhibitor that blocks the activity of HDAC1 and HDAC3, as well as causes hyperacetylation of histone H4 \[[@CR9]\]. SAHA is an analog of TSA that has an extended half-life and improved oral bioavailability \[[@CR14]\]. SAHA has been approved by the FDA as a treatment option for cutaneous T cell lymphoma \[[@CR15]\]. Additionally, it has also been shown that SAHA has synergistic effects with proteasome inhibitors such as carfilzomib, inhibiting T cell leukemia/lymphoma cell growth in an in vivo xenograft model \[[@CR16]\]. Vorinostat is an antineoplastic drug that has been found to have anticryptosporidial effects in mice, where it acts in a dose-dependent manner against parasite oocysts. The estimated in vivo 50% inhibition dose (ID50) value was approximately 7.5 mg/kg \[[@CR17]\]. However, the antifungal potential of SAHA as well as its effects in combination with azoles are still not well understood. The aim of this study was to investigate the effects of SAHA alone as well as in combination with azoles against *Aspergillus* spp. and their biofilms.

Results {#Sec2}
=======

In vitro interactions of SAHA and azoles against planktonic cells {#Sec3}
-----------------------------------------------------------------

The ranges of the MICs (100% inhibition, assessed visually) of SAHA, itraconazole (ITR), voriconazole (VRC), and posaconazole (POC) for isolates of planktonic *Aspergillus* spp. were ≥ 16 μg/ml, 1 to 2 μg/ml, 0.5 to 1 μg/ml, and 0.5 to 1 μg/ml, respectively (Table [1](#Tab1){ref-type="table"}). Moreover, when SAHA was combined with ITR, synergistic effects were observed in 66% (8/12) of *A. fumigatus* strains, 60% (3/5) of *Aspergillus flavus* strains and 33% (1/3) of *Aspergillus terreus* strains. Synergistic effects of SAHA and VRC against *A. fumigatus, A. flavus* and *A. terreus* were apparent in 50% (6/12 strains), 20% (1/5 strains) and 33% (1/3 strains) of strains, respectively. When SAHA was combined with POC against planktonic cells, synergistic effects against *A. fumigatus, A. flavus,* and *A. terreus* were observed for 25% (3/12 strains), 20% (1/5 strains), and 33% (1/3 strains) of strains, respectively (Table [1](#Tab1){ref-type="table"}). Table 1MICs (μg/ml) of the drugs alone and FICIs for combinations of SAHA with azoles against planktonic *Aspergillus* spp.StrainSAHAITRSAHA/ITRFICIVRCSAHA/VRCFICIPOCSAHA/POCFICI*A. fumigatus* AF293≥1624/0.50.3812/0.250.3112/0.250.31 AF102≥1612/0.310.5612/0.50.5612/0.50.56 AF103≥1622/0.50.3112/0.250.3114/0.50.63 AF104≥1622/0.50.3112/0.250.3112/0. 50.56 AF105≥1612/11.0612/0.50.5612/0.250.31 AF106≥1622/0.50.3112/0.250.3112/0.50.56 AF107≥1612/0.250.310.52/0.250.5612/0.50.56 AF108≥1612/0.250.3112/0.1250.1914/0.50.63 AF109≥1622/0.50.3112/0.250.3112/11.06 AF1010≥1622/20.560.52/0.250.560.52/0.51.06 AF1011≥1612/0.50.5612/0.50.5612/0.250.31 AF1012≥1612/0.50.5612/11.0612/0.50.56*A. flavus* AFLA101≥1622/0.50.3112/0.250.310.52/0.51.06 AFLA102≥1622/10.5612/0.50.5612/0.50.56 AFLA103≥1622/0.50.3112/0.250.3112/0.250.31 AFLA104≥1622/0.50.3111/0.50.5312/0.50.56 AFLA105≥1622/10.5612/0.250.3114/11.06*A. terreus* AT101≥1622/0.50.310.51/0.250.5312/0.50.56 AT102≥1622/10.5612/0.250.310.52/0.51.06 AT103≥1612/0.50.5612/0.250.3112/0.250.31FICI results: synergy (FICI of ≤0.5); indifference (no interaction \[FICI of \> 0.5 to ≤4\]). *ITR* itraconazole, *VRC* voriconazole, *POC* posaconazole, *SAHA* suberoylanilide hydroxamic acid

In vitro interactions of SAHA and azoles against biofilms {#Sec4}
---------------------------------------------------------

The sessile minimal inhibitory concentrations (SMIC~80~) were defined as concentrations resulting in an 80% reduction in the metabolic activity of the biofilm. The SMIC~80~ ranges of SAHA, ITR, VRC, and POC against *Aspergillus* biofilms were ≥ 256 g/ml, ≥256 g/ml, 128 to 256 g/ml, and ≥ 256 g/ml, respectively (Table [2](#Tab2){ref-type="table"}). SMIC values were greater than the MICs for each drug. When SAHA was combined with ITR against *Aspergillus* biofilms, the fractional inhibitory concentration index (FICI) was calculated from the SMIC~80~. Similar synergistic effects were observed against 16 isolates of *Aspergillus* spp., consisting of 11 strains of *A. fumigatus* (11/12), four strains of *A. flavus* (4/5) and one strain of *A. terreus* (1/3). For the SAHA and VRC combination, the FICIs displayed synergistic effects against eight strains of *A. fumigatus* (8/12), five strains of *A. flavus* (5/5) and one strain of *A. terreus* (1/3). For the combination of SAHA and POC, the FICIs revealed synergistic effects against 13 strains. No antagonistic effects were observed in these combinations. Table 2SMIC80 and FICIs of combinations of SAHA with azoles against *Aspergillus* biofilmsStrainSMIC~80~ (μg/ml)SMIC~80~SMIC~80~SAHAVRCSAHA/VRCFICIITRSAHA/ITRFICIPOCSAHA/POCFICIAF293≥256≥256128/1280.50≥256128/640.38≥256128/1280.50AF102≥256≥256128/1280.50≥256128/1280.50≥256128/2560.75AF103≥256128128/320.50≥256128/2560.75≥256128/2560.75AF104≥256≥25664/640.25≥25664/640.25≥256128/1280.50AF105≥256≥256128/1280.50≥25664/1280.38≥25664/640.25AF106≥256≥256128/1280.50≥256128/1280.50≥256128/1280.50AF107≥256128128/640.75≥256128/1280.50≥256128/1280.50AF108≥256256128/1280.75≥25664/640.25256128/1280.75AF109≥25625664/320.25≥256128/1280.50256128/1280.75AF1010≥256128128/640.75≥256128/1280.50≥256128/1280.50AF1011≥25612864/640.63≥256128/1280.50≥256128/1280.50AF1012≥25612864/320.38≥256128/1280.50≥256128/2560.75AFLA1≥256≥256128/1280.50≥256128/1280.50256128/1280.75AFLA2≥256≥256128/1280.50≥256128/1280.50≥256128/1280.50AFLA3≥256≥256128/1280.50≥256128/1280.50≥25664/640.25AFLA4≥256≥256128/640.38≥256128/1280.50≥256128/1280.50AFLA5≥256≥256128/1280.50≥256128/2560.75≥256128/1280.50AT101≥256128128/1281.25≥256128/2560.75≥256128/1280.50AT102≥25612864/640.63≥256128/2560.75≥256128/2560.75AT103≥256≥25664/640.25≥256128/1280.50≥256128/1280.50FICI results: synergy (FICI of ≤0.5); indifference (no interaction \[FICI of \> 0.5 to ≤4\]). *ITR* itraconazole, *VRC* voriconazole, *POC* posaconazole, *SAHA* suberoylanilide hydroxamic acid

Triple combinations with TSA {#Sec5}
----------------------------

Synergistic interactions were also observed with the triple combinations. After adding 2 μg/ml TSA to each group, the FICIs of the different combinations were no different from those of SAHA combined with azoles only (data were the same as those shown in Table [1](#Tab1){ref-type="table"}). There was also no observed antagonism.

Quantification of gene expression by RT--PCR {#Sec6}
--------------------------------------------

To determine whether the synergistic mechanism of SAHA with azoles against *A. fumigatus* is due to down-regulation of efflux pump genes or *HSP90*, qRT-PCR was performed to analyze the expression levels of these genes under conditions of SAHA or azole treatment alone as well as in combination.

As shown in Fig. [1](#Fig1){ref-type="fig"}, all the MDR-related efflux pump genes and *HSP90* tested in this study were up-regulated in both the azole-treated and SAHA-only groups. Further assessment indicated that the expression of these genes is suppressed when azoles and SAHA are used in combination. This observation was especially evident in the case of *HSP90*. The expression of *HSP90* was reduced by 6.8-fold in response to treatment with ITR with SAHA, 2.5-fold in response to treatment with ITR with SAHA, and 8.25-fold in response to treatment with ITR with SAHA compared to that with azole-only treatment. Moreover, the attenuated expression of the efflux pump genes was relatively mild in the combination groups compared to that in the azole-alone groups (1.3- to 2.6-fold). Only MDR1 was repressed (by 5.7-fold) when SAHA was combined with POC compared to that with POC alone (*p* \< 0.05). Fig. 1Relative expression levels of the drug efflux pump genes and *HSP90* in AF293 cells after drug treatment. **a** Expression levels of Genes in SAHA, ITR and ITR + SAHA treated groups; **b** Expression levels of Genes in VRC and VRC + SAHA treated groups; **c** Expression levels of Genes in POC and POC + SAHA treated groups. Assays were carried out in triplicate by biological replication and analyzed for statistical significance by multiple t tests using GraphPad Prism Software. The results are significantly different between azoles alone and azoles+SAHA combinations (\*: *P* values \<0.05). ITR: itraconazole; VRC: voriconazole; POC: posaconazole; SAHA: suberoylanilide hydroxamic acid

These results show that the synergy of SAHA with azoles may be associated with suppression of *HSP90* expression*.* This finding is consistent with a previously published report on the effects of TSA \[[@CR9]\]. However, this synergy has very little effect, if any, on the inhibition of efflux pump genes in *A. fumigatus*.

Discussion {#Sec7}
==========

In *Aspergillus*, HDACs influence virulence by controlling transcription and regulating essential protein functions \[[@CR9]\]. The findings of the current study show that the new HDAC inhibitor SAHA is not effective against all planktonic and biofilm isolates of *Aspergillus* spp. However, combinations of SAHA with azoles showed synergistic effects against most planktonic cells and biofilms. This effect was most noticeable when SAHA was combined with ITR or VRC, although there were weak synergistic effects between SAHA and POC. In addition, SAHA was able to strengthen the antifungal effects of azoles. The half-maximal effective concentration (EC50) of SAHA against another human pathogen, *Cryptosporidium parvum,* has been reported as 0.203 μM \[[@CR17]\]. Despite of a lack of inhibitory effects of SAHA against *Aspergillus*, the synergistic effects observed with the azole combination indicate that the MICs of SAHA may be acceptable for in vivo treatment. The effective doses of SAHA (400 mg/day oral dose for adults) would be able to reach the effective concentration that, with the addition of azoles, could make it appropriate for the treatment of aspergillosis. The mechanisms of resistance of *A. fumigatus* biofilms to antifungal drugs are strongly associated with genes encoding ABC transporters \[[@CR6]\]. HSP90 is also involved in the resistance of *A. fumigatus* biofilms to drugs, and impairment of HSP90 function could reverse azole resistance in eradicating biofilms \[[@CR18]\]. Furthermore, blocking the action of HSP90 increases the azole sensitivity of fungi \[[@CR19]\]. To explain the probable synergistic effects of SAHA and azoles against *Aspergillus* or its biofilm, the expression of the azole susceptibility-related drug efflux pumps *MDR1*, *MDR2*, *MDR3*, and *MDR4,* as well as *HSP90* levels, was measured by RT-PCR. The results showed that the molecular mechanism of the observed SAHA synergistic effects with azoles in *A. fumigatus* biofilms might be associated with diminished expression of these efflux pumps. Although the diminished expression of efflux pump genes was comparatively mild in the combination groups compared with that in the azole-only groups (1.3- to 2.6-fold) and in the combinations of SAHA with VRC and POC, the expression of all four efflux pump genes showed a statistically significant reduction compared with that after azole treatment alone (Fig. [1](#Fig1){ref-type="fig"}). The precise effects of altered expression of these efflux pumps need to be further investigated by using different knockout strains. Inactivation of HDACs in *C. albicans* was observed to block the HSP90-dependent response involved in azole resistance and restore azole susceptibility \[[@CR6]\]. In our study, by using TSA as a rescue agent, the FICIs of different combination groups showed no change, confirming that the main synergistic mechanism of SAHA with azoles was mediated by HDAC inhibition. HDACs deacetylate and control the activation of multiple cytosolic proteins, such as HSP90 \[[@CR9]\]. TSA is able to inhibit both class 1 and class 2 HDACs, thus displaying antifungal activity against *A. fumigatus* and having a similar phenotype to genetic repression of *HSP90* \[[@CR20]\]. In the present study, the expression levels of *HSP90* were significantly suppressed in the SAHA combination groups compared with those in the azole-only groups. This suppression of *HSP90* was consistent with the reported actions of TSA, which supports the hypothesis that the synergistic effects of SAHA with azoles are mediated through *HSP90* inhibition. Further investigation of the relationship between *HSP90* and SAHA and their pathways in *Aspergillus* virulence and azole susceptibility may help to understand the mechanisms of the observed synergistic interactions. HDAC inhibitors have the potential to act as anticancer agents, which may motivate clinical as well as preclinical trials. There is thus a strong incentive to further research HDAC inhibitors, including SAHA, to gain insight into and understanding of the role of HDACs in fungi, as well as to investigate more effective therapeutic strategies against infections caused by *Aspergillus.*

Conclusions {#Sec8}
===========

In the current study, investigation of the HDAC inhibitor SAHA demonstrated its potential as a secondary treatment to improve the effects of azole treatment against both biofilm and planktonic states of *Aspergillus spp.* This activity appears to occur largely via the inhibition of *HSP90*. Future in vivo studies as well as studies focusing on underlying mechanisms will be beneficial to understand the clinical use of these combinations against *Aspergillus*-associated infections.

Methods {#Sec9}
=======

Fungal strains {#Sec10}
--------------

A total of 20 strains of *Aspergillus* spp. comprising twelve strains of *A. fumigatus* (AF102-AF1010 were isolated from IA patients; AF1011 and AF1012 were isolated from chronic rhinosinusitis patients), five strains of *A. flavus* (AFLA101-AFLA103 were isolated from IA patients; AFLA104 and AFLA105 were isolated from chronic rhinosinusitis patients), and three strains of *A. terreus* (AT101-AT103 were isolated from chronic rhinosinusitis patients) were studied. All the clinical strains were acquired from patients admitted to our hospital. All patients provided written informed consent. This study was approved by the patients as well as the Research Ethics Committee of the First Affiliated Hospital Jinan University. Both microscopic morphology and sequencing of the ITS were performed for fungal identification. *A. flavus* strain ATCC 204304 was included as a quality control.

Patient information {#Sec11}
-------------------

AF102-AF1010 and AFLA101-AFLA103 were isolated from patients with acute leukemia with IA during systemic chemotherapy. AF1011, AF1012, AFLA104, AFLA105 and AT101-AT103 were isolated from patients with chronic rhinosinusitis without invasive infection.

Antifungal and chemical agents {#Sec12}
------------------------------

All tested drugs, including SAHA (purity ≥99%), itraconazole (ITR, purity ≥99%), voriconazole (VRC, purity ≥99%), posaconazole (POC, purity ≥99%) and TSA (purity ≥97%), were bought in powder form from Selleck Chemicals (Houston, TX, USA) and prepared as described in the Clinical and Laboratory Standards Institute (CLSI) broth microdilution method M38-A2 \[[@CR21]\]. All the drugs were dissolved in DMSO to formulate stock solutions with a concentration of 6400 μg/ml. The working concentration ranges for antifungal tests and antifungal combinations of SAHA, ITR, VRC, and POC were 0.03--16 μg/ml for planktonic cells and 2--256 μg/ml for biofilms.

Preparation of inoculums {#Sec13}
------------------------

Fresh conidia collected from Sabouraud dextrose agar (SDA) cultures were suspended in sterile distilled water containing 0.03% Triton. A hemocytometer was used to adjust the concentrations to 1--5 × 10^6^ spores/ml, which were then diluted 100 times in RPMI-1640 buffered with 165 mM morpholinepropanesulfonic acid to pH 7. The final densities of conidia were approximately 1--5 × 10^4^ spores/ml \[[@CR11]\].

Preparation of biofilms {#Sec14}
-----------------------

*Aspergillus* biofilms were prepared as previously described \[[@CR22]\]. Fresh conidia on SDA were collected and suspended in 20 ml of RPMI-1640 according to the supplier's protocol. The cells were suspended in RPMI-1640 to a final concentration of 1.0 × 10^5^ cells/ml. Subsequently, 200 μl of the suspension was added to wells of 96-well plates and incubated at 37 °C for 48 h. After the maturation of the biofilms, the medium was carefully removed without disturbing the biofilm. The 96-well plates were then washed carefully three times with sterile PBS to remove detached spores \[[@CR22]\].

In vitro interactions of SAHA and azoles against planktonic forms {#Sec15}
-----------------------------------------------------------------

The microdilution chequerboard technique and CLSI broth microdilution method M38-A2 were used to evaluate the combinations of SAHA and azoles \[[@CR11], [@CR21]\]. Specifically, serial dilutions of 50 μl of SAHA and 50 μl of azoles were added in the horizontal and vertical directions, respectively, of the 96-well plates. The final volume of each well was 200 μl containing 100 μl of prepared inoculum suspension plus 100 μl of drugs. After incubation at 35 °C for 48 h, the MIC values of SAHA and azoles were recorded as the lowest concentration leading to complete inhibition of growth, as assessed visually. The FICI was used to classify the interactions of drug combinations. For the concentration of MICs used for the FICI calculation that was above the maximum concentration tested, we used double this value. The FICIs were calculated by MIC as previously described \[[@CR11]\]. The FICI was classified as follows: FICI of ≤0.5, synergy; FICI of \>0.5 to ≤4, no interaction; and FICI of \>4, antagonism. All tests were performed in triplicate by biological replication \[[@CR23]\].

In vitro interactions of SAHA and azoles against biofilms {#Sec16}
---------------------------------------------------------

Using the checkerboard method, SAHA and azoles were added to 96-well plates containing the prepared biofilms. The XTT-based colorimetric assay was used. Briefly, azoles or SAHA were added first to biofilm-containing wells, followed by incubation at 37 °C for 24 h and subsequent addition of μl XTT/menadione solution to each well and further incubation for 2 h at 37 °C. Finally, 80 μl of the colored supernatant from each well was transferred into a new 96-well plate. This new 96-well plate was read at 490 nm to lessen the color influence of spores or biofilms. The SMIC80 was read as an 80% decrease in optical density compared to that of the controls. The interactions of SAHA with azoles against the biofilms also were analyzed by FICI, which was based on the SMIC80 \[[@CR24]\]. All experiments were performed in triplicate by biological replication.

Triple combinations with TSA {#Sec17}
----------------------------

To determine whether the synergistic effects of SAHA with azoles are due to the inhibition of HDACs, we added triple combinations of drugs with a three-dimensional checkerboard technique based on CLSI M38-A2 \[[@CR25]\]. SAHA and azoles (ITR, VRC and POC) were laid out according to the double combinations, followed by the addition of a single concentration (2 μg/ml) of TSA to each plate, from which we were able to determine the MIC of each agent alone and the combined effects on the same plate. The concentrations of SAHA, ITR, VRC, and POC ranged from 0.03--16 μg/ml. Quality controls were also included. After incubation for 48 h, the MICs were determined visually as the lowest concentration exhibiting total inhibition of growth.

Quantification of gene expression by RT--PCR {#Sec18}
--------------------------------------------

One-step RT--PCR was performed on an ABI 7500 machine according to the manufacturer's instructions. Primers for *HSP90, MDR1, MDR2, MDR3, MDR4* and β-tubulin (synthesized by Shanghai Samgon Biotech Co., Ltd.) \[[@CR26], [@CR27]\] are listed in Table [3](#Tab3){ref-type="table"}. Approximately 1 × 10^6^ cells/ml AF293 cells were incubated on a shaker (200 rpm) at 37 °C for 10 h in RPMI-1640 medium. Subinhibitory concentrations of azoles alone (0.25 μg/ml for ITR, 0.125 μg/ml for VRC, and 0.125 μg/ml for POC) or in combination with SAHA (4 μg/ml) were added to the media, in addition to a drug-free control. The chosen doses of drugs were based on the antifungal susceptibility test; however, they did not directly correlate with the FICIs. TRIzol and acid-washed glass beads were used to extract total RNA. cDNA was synthesized by using TransScript II First-Strand cDNA Synthesis SuperMix (Transgen Biotec, Beijing, China). qRT--PCR was performed using TransScript II Green One-Step qRT-PCR SuperMix (Transgen Biotec, Beijing, China) according to the supplier's protocol. Amplification was achieved under the following conditions: 50 °C for 5 min, 94 °C for 30 s, and 40 cycles of 95 °C for 30 s followed by 60 °C for 30 s. Dissociation curves were examined to rule out any nontarget amplification. Gene expression was evaluated using the 2^-ΔΔCt^ method, with β-tubulin as the reference gene \[[@CR27]\]. Table 3Primers used in this studyPrimerSequence*HSP90*5′-TCATGATCGCTCCATGTTG-3′5′-GAGGAGCTCAACAAGACCAA-3'*MDR1*5′-GAACGCACCACGAGTTGATT-3'5′-CTGCAGATTGACCAGCTCGTAATA-3'*MDR2*5′-CTTGTTATCCGCCAATGTCTGTAGT-3'5′-GGAGGTAGAAAACAGCCTGACT-3'*MDR3*5′-CATCCTCATTCCCTTGCATATCGT-3'5′-TCAAGCTATAACCGCCCACATG-3'*MDR4*5′-TTGCTGGTGTTTGGTGAGTGA-3'5′-GCCTCCTGTTTGATAATGCTCTCA-3'*β-tubulin*5′-GCACGTGAAATTGTTGAAAGG-3'5′-CAGGCTGGCCGCATTG-3'

Statistical analysis {#Sec19}
--------------------

RT-PCR values were expressed as the means and standard errors of the mean (error bars), and graphs were generated using GraphPad Prism (version 6). Statistical analysis was performed by multiple t tests. The results were considered statistically significant at *P\<*0.05.

FICI

:   Fractional inhibitory concentration index

HDACs

:   Histone deacetylases

IA

:   Invasive aspergillosis

ITR

:   Itraconazole

MIC

:   Minimal inhibitory concentration

POC

:   Posaconazole

SAHA

:   Suberoylanilide hydroxamic acid

SDA

:   Sabouraud dextrose agar

SMIC

:   Sessile minimal inhibitory concentration

VRC

:   Voriconazole

XTT

:   2,3-Bis-\[2-methoxy-4-nitro-5-sulfophenyl\]-2H-tetrazolium-5-carboxanilide
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